Details for Patent: 4,415,558

Summary for Patent: 4,415,558

Title:	CRF And analogs
Abstract:	CRF (Corticotropin Releasing Factor) has the formula: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-L eu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu- Leu-Asp-Ile-Ala-NH.sub.2. Analogs have been synthesized that are at least as potent as CRF, and CRF or these analogs or pharmaceutically acceptable salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals to achieve a substantial elevation of ACTH, .beta.-endorphin, .beta.-lipotropin and corticosterone levels and/or a lowering of blood pressure over an extended period of time. In the analogs, one or more of the first three N-terminal residues may be deleted or may be substituted by a peptide up to 10 amino acids long and/or by an acylating agent containing up to 7 carbon atoms. Ala in the 41-position may also be substituted or deleted so long as the remaining C-terminus is amidated. Several other substitutions may also be made throughout the chain.
Inventor(s):	Vale, Jr.; Wylie W. (La Jolla, CA), Spiess; Joachim (Encinatas, CA), Rivier; Catherine L. (La Jolla, CA), Rivier; Jean E. F. (La Jolla, CA)
Assignee:	The Salk Institute for Biological Studies (San Diego, CA)
Application Number:	06/378,999
Patent Claim Types: see list of patent claims	Composition; Compound; Use;

Drugs Protected by US Patent 4,415,558

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,415,558

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	6505
Australia	554676
Australia	8445582
Canada	1243301
Germany	3260057
Denmark	156957
Denmark	254982